Docetaxel (Taxotere®)

Common name: Docetaxel
Brand name: Taxotere®
 

What is Docetaxel?

Docetaxel is a chemotherapy drug used in combination with a corticosteroid (such as prednisone or prednisolone) to treat androgen-independent metastatic prostate cancer.


How is Docetaxel administered?

Docetaxel is administered by injection.

What are possible side effects of this treatment?

Everyone responds differently to chemotherapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received docetaxel. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Anemia
  • Bruising / bleeding
  • Changes to taste
  • Diarrhea
  • Fatigue
  • Fluid retention
  • Hair loss
  • Infection
  • Increase in production of tears
  • Loss of appetite
  • Mouth sores
  • Nausea / vomiting
  • Numbness, burning, tingling in hands and feet
  • Pain in joints
  • Rash

Is Docetaxel covered in my province or territory?

Docetaxel is covered by provincial drug programs in:
 
•    Alberta
•    British Columbia
•    Nova Scotia
•    Ontario
•    Quebec
•    Saskatchewan
•    Yukon
 
Docetaxel is not covered by provincial drug programs in:
 
•    New Brunswick
•    Newfoundland & Labrador
•    Prince Edward Island
•    Nunavut
•    Northwest Territories

Unknown if docetaxel is covered by provincial drug programs in:
•    Manitoba



 
    Last Reviewed: July 2017








Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
1.5 million Canadian men over 50 now at unnecessary risk for prostate cancer

Toronto (ON) – September 26, 2019 – New findings released today in a Prostate Cancer Canada nationwide survey suggest 1.
More

$2 million invested in new prostate cancer research

Prostate Cancer Canada and Movember partner to fund ten research projects breaking new ground
More

Dream car draw a win for all Ontarians affected by prostate cancer

February 22, 2019 – TORONTO, ON – A dream came true today for Harold Mutter (ticket #19273), the lucky winner of a 2018 Acura NSX valued at more than $235,000 - the prize for Prostate Cancer Canada’s seventh Rock the Road Raffle.
More

Researchers discover common markers of tumour hypoxia across 19 cancer types

Landmark pan-cancer study analyzes mutation signatures of low oxygen in more than 8,000 tumours
More

Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More


Click here for news archive